Predictors of response to tiotropium versus salmeterol in asthmatic adults

Stephen P. Peters, Eugene R. Bleecker, Susan J. Kunselman, Nikolina Icitovic, Wendy C. Moore, Rodolfo Pascual, Bill Ameredes, Homer A. Boushey, William Calhoun, Mario Castro, Reuben M. Cherniack, Timothy Craig, Loren C. Denlinger, Linda L. Engle, Emily A. Dimango, Elliot Israel, Monica Kraft, Stephen C. Lazarus, Robert F. Lemanske, Njira Lugogo & 10 others Richard J. Martin, Deborah A. Meyers, Joe Ramsdell, Christine A. Sorkness, E. Rand Sutherland, Stephen I. Wasserman, Michael J. Walter, Michael E. Wechsler, Vernon M. Chinchilli, Stanley J. Szefler

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background Tiotropium has activity as an asthma controller. However, predictors of a positive response to tiotropium have not been described. Objective We sought to describe individual and differential responses of asthmatic patients to salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a positive clinical response. Methods Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials.gov number, NCT00565266) trial were analyzed for individual and differential treatment responses to salmeterol and tiotropium and predictors of a positive response to the end points FEV1, morning peak expiratory flow (PEF), and asthma control days (ACDs). Results Although approximately equal numbers of patients showed a differential response to salmeterol and tiotropium in terms of morning PEF (n = 90 and 78, respectively) and ACDs (n = 49 and 53, respectively), more showed a differential response to tiotropium for FEV1 (n = 104) than salmeterol (n = 62). An acute response to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tiotropium for FEV1 (odds ratio, 4.08; 95% CI, 2.00-8.31; P <.001) and morning PEF (odds ratio, 2.12; 95% CI, 1.12-4.01; P = 0.021), as did a decreased FEV1/forced vital capacity ratio (FEV1 response increased 0.39% of baseline for every 1% decrease in FEV1/forced vital capacity ratio). Higher cholinergic tone was also a predictor, whereas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asthma duration, and body mass index were not. Conclusion Although these results require confirmation, predictors of a positive clinical response to tiotropium include a positive response to albuterol and airway obstruction, factors that could help identify appropriate patients for this therapy.

Original languageEnglish (US)
Pages (from-to)1068-1074
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume132
Issue number5
DOIs
StatePublished - Nov 2013

Fingerprint

Asthma
Albuterol
Vital Capacity
Adrenal Cortex Hormones
Odds Ratio
National Heart, Lung, and Blood Institute (U.S.)
Tiotropium Bromide
Salmeterol Xinafoate
Bronchodilator Agents
Airway Obstruction
Sputum
Double-Blind Method
Eosinophils
Cholinergic Agents
Immunoglobulin E
Glucocorticoids
Nitric Oxide
Body Mass Index
Therapeutics
Research

Keywords

  • Asthma
  • predictor of response
  • responder analysis
  • salmeterol
  • tiotropium

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Peters, S. P., Bleecker, E. R., Kunselman, S. J., Icitovic, N., Moore, W. C., Pascual, R., ... Szefler, S. J. (2013). Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology, 132(5), 1068-1074. https://doi.org/10.1016/j.jaci.2013.08.003

Predictors of response to tiotropium versus salmeterol in asthmatic adults. / Peters, Stephen P.; Bleecker, Eugene R.; Kunselman, Susan J.; Icitovic, Nikolina; Moore, Wendy C.; Pascual, Rodolfo; Ameredes, Bill; Boushey, Homer A.; Calhoun, William; Castro, Mario; Cherniack, Reuben M.; Craig, Timothy; Denlinger, Loren C.; Engle, Linda L.; Dimango, Emily A.; Israel, Elliot; Kraft, Monica; Lazarus, Stephen C.; Lemanske, Robert F.; Lugogo, Njira; Martin, Richard J.; Meyers, Deborah A.; Ramsdell, Joe; Sorkness, Christine A.; Sutherland, E. Rand; Wasserman, Stephen I.; Walter, Michael J.; Wechsler, Michael E.; Chinchilli, Vernon M.; Szefler, Stanley J.

In: Journal of Allergy and Clinical Immunology, Vol. 132, No. 5, 11.2013, p. 1068-1074.

Research output: Contribution to journalArticle

Peters, SP, Bleecker, ER, Kunselman, SJ, Icitovic, N, Moore, WC, Pascual, R, Ameredes, B, Boushey, HA, Calhoun, W, Castro, M, Cherniack, RM, Craig, T, Denlinger, LC, Engle, LL, Dimango, EA, Israel, E, Kraft, M, Lazarus, SC, Lemanske, RF, Lugogo, N, Martin, RJ, Meyers, DA, Ramsdell, J, Sorkness, CA, Sutherland, ER, Wasserman, SI, Walter, MJ, Wechsler, ME, Chinchilli, VM & Szefler, SJ 2013, 'Predictors of response to tiotropium versus salmeterol in asthmatic adults', Journal of Allergy and Clinical Immunology, vol. 132, no. 5, pp. 1068-1074. https://doi.org/10.1016/j.jaci.2013.08.003
Peters SP, Bleecker ER, Kunselman SJ, Icitovic N, Moore WC, Pascual R et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. Journal of Allergy and Clinical Immunology. 2013 Nov;132(5):1068-1074. https://doi.org/10.1016/j.jaci.2013.08.003
Peters, Stephen P. ; Bleecker, Eugene R. ; Kunselman, Susan J. ; Icitovic, Nikolina ; Moore, Wendy C. ; Pascual, Rodolfo ; Ameredes, Bill ; Boushey, Homer A. ; Calhoun, William ; Castro, Mario ; Cherniack, Reuben M. ; Craig, Timothy ; Denlinger, Loren C. ; Engle, Linda L. ; Dimango, Emily A. ; Israel, Elliot ; Kraft, Monica ; Lazarus, Stephen C. ; Lemanske, Robert F. ; Lugogo, Njira ; Martin, Richard J. ; Meyers, Deborah A. ; Ramsdell, Joe ; Sorkness, Christine A. ; Sutherland, E. Rand ; Wasserman, Stephen I. ; Walter, Michael J. ; Wechsler, Michael E. ; Chinchilli, Vernon M. ; Szefler, Stanley J. / Predictors of response to tiotropium versus salmeterol in asthmatic adults. In: Journal of Allergy and Clinical Immunology. 2013 ; Vol. 132, No. 5. pp. 1068-1074.
@article{b4692125f978402da9cae52f35a9de55,
title = "Predictors of response to tiotropium versus salmeterol in asthmatic adults",
abstract = "Background Tiotropium has activity as an asthma controller. However, predictors of a positive response to tiotropium have not been described. Objective We sought to describe individual and differential responses of asthmatic patients to salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a positive clinical response. Methods Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials.gov number, NCT00565266) trial were analyzed for individual and differential treatment responses to salmeterol and tiotropium and predictors of a positive response to the end points FEV1, morning peak expiratory flow (PEF), and asthma control days (ACDs). Results Although approximately equal numbers of patients showed a differential response to salmeterol and tiotropium in terms of morning PEF (n = 90 and 78, respectively) and ACDs (n = 49 and 53, respectively), more showed a differential response to tiotropium for FEV1 (n = 104) than salmeterol (n = 62). An acute response to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tiotropium for FEV1 (odds ratio, 4.08; 95{\%} CI, 2.00-8.31; P <.001) and morning PEF (odds ratio, 2.12; 95{\%} CI, 1.12-4.01; P = 0.021), as did a decreased FEV1/forced vital capacity ratio (FEV1 response increased 0.39{\%} of baseline for every 1{\%} decrease in FEV1/forced vital capacity ratio). Higher cholinergic tone was also a predictor, whereas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asthma duration, and body mass index were not. Conclusion Although these results require confirmation, predictors of a positive clinical response to tiotropium include a positive response to albuterol and airway obstruction, factors that could help identify appropriate patients for this therapy.",
keywords = "Asthma, predictor of response, responder analysis, salmeterol, tiotropium",
author = "Peters, {Stephen P.} and Bleecker, {Eugene R.} and Kunselman, {Susan J.} and Nikolina Icitovic and Moore, {Wendy C.} and Rodolfo Pascual and Bill Ameredes and Boushey, {Homer A.} and William Calhoun and Mario Castro and Cherniack, {Reuben M.} and Timothy Craig and Denlinger, {Loren C.} and Engle, {Linda L.} and Dimango, {Emily A.} and Elliot Israel and Monica Kraft and Lazarus, {Stephen C.} and Lemanske, {Robert F.} and Njira Lugogo and Martin, {Richard J.} and Meyers, {Deborah A.} and Joe Ramsdell and Sorkness, {Christine A.} and Sutherland, {E. Rand} and Wasserman, {Stephen I.} and Walter, {Michael J.} and Wechsler, {Michael E.} and Chinchilli, {Vernon M.} and Szefler, {Stanley J.}",
year = "2013",
month = "11",
doi = "10.1016/j.jaci.2013.08.003",
language = "English (US)",
volume = "132",
pages = "1068--1074",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Predictors of response to tiotropium versus salmeterol in asthmatic adults

AU - Peters, Stephen P.

AU - Bleecker, Eugene R.

AU - Kunselman, Susan J.

AU - Icitovic, Nikolina

AU - Moore, Wendy C.

AU - Pascual, Rodolfo

AU - Ameredes, Bill

AU - Boushey, Homer A.

AU - Calhoun, William

AU - Castro, Mario

AU - Cherniack, Reuben M.

AU - Craig, Timothy

AU - Denlinger, Loren C.

AU - Engle, Linda L.

AU - Dimango, Emily A.

AU - Israel, Elliot

AU - Kraft, Monica

AU - Lazarus, Stephen C.

AU - Lemanske, Robert F.

AU - Lugogo, Njira

AU - Martin, Richard J.

AU - Meyers, Deborah A.

AU - Ramsdell, Joe

AU - Sorkness, Christine A.

AU - Sutherland, E. Rand

AU - Wasserman, Stephen I.

AU - Walter, Michael J.

AU - Wechsler, Michael E.

AU - Chinchilli, Vernon M.

AU - Szefler, Stanley J.

PY - 2013/11

Y1 - 2013/11

N2 - Background Tiotropium has activity as an asthma controller. However, predictors of a positive response to tiotropium have not been described. Objective We sought to describe individual and differential responses of asthmatic patients to salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a positive clinical response. Methods Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials.gov number, NCT00565266) trial were analyzed for individual and differential treatment responses to salmeterol and tiotropium and predictors of a positive response to the end points FEV1, morning peak expiratory flow (PEF), and asthma control days (ACDs). Results Although approximately equal numbers of patients showed a differential response to salmeterol and tiotropium in terms of morning PEF (n = 90 and 78, respectively) and ACDs (n = 49 and 53, respectively), more showed a differential response to tiotropium for FEV1 (n = 104) than salmeterol (n = 62). An acute response to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tiotropium for FEV1 (odds ratio, 4.08; 95% CI, 2.00-8.31; P <.001) and morning PEF (odds ratio, 2.12; 95% CI, 1.12-4.01; P = 0.021), as did a decreased FEV1/forced vital capacity ratio (FEV1 response increased 0.39% of baseline for every 1% decrease in FEV1/forced vital capacity ratio). Higher cholinergic tone was also a predictor, whereas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asthma duration, and body mass index were not. Conclusion Although these results require confirmation, predictors of a positive clinical response to tiotropium include a positive response to albuterol and airway obstruction, factors that could help identify appropriate patients for this therapy.

AB - Background Tiotropium has activity as an asthma controller. However, predictors of a positive response to tiotropium have not been described. Objective We sought to describe individual and differential responses of asthmatic patients to salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a positive clinical response. Methods Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials.gov number, NCT00565266) trial were analyzed for individual and differential treatment responses to salmeterol and tiotropium and predictors of a positive response to the end points FEV1, morning peak expiratory flow (PEF), and asthma control days (ACDs). Results Although approximately equal numbers of patients showed a differential response to salmeterol and tiotropium in terms of morning PEF (n = 90 and 78, respectively) and ACDs (n = 49 and 53, respectively), more showed a differential response to tiotropium for FEV1 (n = 104) than salmeterol (n = 62). An acute response to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tiotropium for FEV1 (odds ratio, 4.08; 95% CI, 2.00-8.31; P <.001) and morning PEF (odds ratio, 2.12; 95% CI, 1.12-4.01; P = 0.021), as did a decreased FEV1/forced vital capacity ratio (FEV1 response increased 0.39% of baseline for every 1% decrease in FEV1/forced vital capacity ratio). Higher cholinergic tone was also a predictor, whereas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asthma duration, and body mass index were not. Conclusion Although these results require confirmation, predictors of a positive clinical response to tiotropium include a positive response to albuterol and airway obstruction, factors that could help identify appropriate patients for this therapy.

KW - Asthma

KW - predictor of response

KW - responder analysis

KW - salmeterol

KW - tiotropium

UR - http://www.scopus.com/inward/record.url?scp=84887024692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887024692&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2013.08.003

DO - 10.1016/j.jaci.2013.08.003

M3 - Article

VL - 132

SP - 1068

EP - 1074

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -